FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1673408032> ?p ?o ?g. }

• W1673408032 endingPage "7" @default.
• W1673408032 startingPage "3132" @default.
• W1673408032 abstract "Breast cancers with high expression of HER2 are associated frequently with aggressive, poor prognosis disease and resistance to chemotherapy-induced apoptosis. Geldanamycin and its less toxic analogue, 17- (allylamino)-17-demethoxygeldanamycin (17-AAG) are ansamycin antibiotics that bind to a highly conserved pocket in the hsp 90 chaperone protein and inhibit its function. Hsp 90 is required for the refolding of proteins during environmental stress and the conformational maturation of certain signaling proteins. Among the most sensitive targets of 17-AAG are the HER kinases. Therefore, tumors that are dependent on these kinases may be especially sensitive to 17-AAG either alone or in combination with chemotherapy. In this study we demonstrate that cells that overexpress HER2 are 10-100-fold more sensitive to 17-AAG than cancer cells expressing low levels of HER2. We found that HER2 is degraded in several cell lines, but only cell lines with high levels of HER2 are sensitive to the drug. The effects of 17-AAG on growth and apoptosis are because of inhibition of signaling through HER2-HER3, phosphatidylinositol 3'- kinase. The absence of HER3 and the introduction of constitutively active p110alpha rendered cells with high HER2 expression more resistant to 17-AAG. These findings suggest that 17-AAG may be useful for the treatment of breast cancer cells with high levels of HER2. However, the overexpression of HER2 alone may not be predictive of response, because the coexpression of HER3 and the activation of phosphatidylinositol 3'-kinase may play a crucial role in the response of these cells to 17-AAG and other drugs directed against HER2. These observations have important clinical implications because they may help to identify patients that are most likely to benefit from 17-AAG and may explain resistance to Herceptin as seen in many patients." @default.
• W1673408032 created "2016-06-24" @default.
• W1673408032 creator A5031609787 @default.
• W1673408032 creator A5060228803 @default.
• W1673408032 creator A5064856723 @default.
• W1673408032 creator A5083373965 @default.
• W1673408032 date "2002-06-01" @default.
• W1673408032 modified "2023-10-06" @default.
• W1673408032 title "Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway." @default.
• W1673408032 cites W1525412860 @default.
• W1673408032 cites W1753563681 @default.
• W1673408032 cites W1956960611 @default.
• W1673408032 cites W1976558852 @default.
• W1673408032 cites W1978410554 @default.
• W1673408032 cites W1986242330 @default.
• W1673408032 cites W1999794575 @default.
• W1673408032 cites W1999938778 @default.
• W1673408032 cites W2001215449 @default.
• W1673408032 cites W2002079983 @default.
• W1673408032 cites W2002582727 @default.
• W1673408032 cites W2023942550 @default.
• W1673408032 cites W2026389696 @default.
• W1673408032 cites W2049546697 @default.
• W1673408032 cites W2062713892 @default.
• W1673408032 cites W2069412625 @default.
• W1673408032 cites W2077322645 @default.
• W1673408032 cites W2080019220 @default.
• W1673408032 cites W2082258814 @default.
• W1673408032 cites W2095156669 @default.
• W1673408032 cites W2105516763 @default.
• W1673408032 cites W2112133866 @default.
• W1673408032 cites W2112522176 @default.
• W1673408032 cites W2124705172 @default.
• W1673408032 cites W2139306838 @default.
• W1673408032 cites W2141393790 @default.
• W1673408032 cites W2159459001 @default.
• W1673408032 cites W2171091535 @default.
• W1673408032 cites W2173081403 @default.
• W1673408032 cites W2318605753 @default.
• W1673408032 cites W2328470294 @default.
• W1673408032 cites W2402736308 @default.
• W1673408032 cites W279429461 @default.
• W1673408032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12036925" @default.
• W1673408032 hasPublicationYear "2002" @default.
• W1673408032 type Work @default.
• W1673408032 sameAs 1673408032 @default.
• W1673408032 citedByCount "53" @default.
• W1673408032 countsByYear W16734080322012 @default.
• W1673408032 countsByYear W16734080322013 @default.
• W1673408032 countsByYear W16734080322014 @default.
• W1673408032 countsByYear W16734080322015 @default.
• W1673408032 countsByYear W16734080322016 @default.
• W1673408032 countsByYear W16734080322017 @default.
• W1673408032 countsByYear W16734080322018 @default.
• W1673408032 countsByYear W16734080322022 @default.
• W1673408032 crossrefType "journal-article" @default.
• W1673408032 hasAuthorship W1673408032A5031609787 @default.
• W1673408032 hasAuthorship W1673408032A5060228803 @default.
• W1673408032 hasAuthorship W1673408032A5064856723 @default.
• W1673408032 hasAuthorship W1673408032A5083373965 @default.
• W1673408032 hasConcept C104317684 @default.
• W1673408032 hasConcept C121608353 @default.
• W1673408032 hasConcept C184235292 @default.
• W1673408032 hasConcept C190283241 @default.
• W1673408032 hasConcept C205260736 @default.
• W1673408032 hasConcept C2775932338 @default.
• W1673408032 hasConcept C2780297055 @default.
• W1673408032 hasConcept C2780610907 @default.
• W1673408032 hasConcept C502942594 @default.
• W1673408032 hasConcept C54355233 @default.
• W1673408032 hasConcept C55493867 @default.
• W1673408032 hasConcept C62478195 @default.
• W1673408032 hasConcept C75217442 @default.
• W1673408032 hasConcept C86803240 @default.
• W1673408032 hasConcept C95444343 @default.
• W1673408032 hasConcept C96232424 @default.
• W1673408032 hasConceptScore W1673408032C104317684 @default.
• W1673408032 hasConceptScore W1673408032C121608353 @default.
• W1673408032 hasConceptScore W1673408032C184235292 @default.
• W1673408032 hasConceptScore W1673408032C190283241 @default.
• W1673408032 hasConceptScore W1673408032C205260736 @default.
• W1673408032 hasConceptScore W1673408032C2775932338 @default.
• W1673408032 hasConceptScore W1673408032C2780297055 @default.
• W1673408032 hasConceptScore W1673408032C2780610907 @default.
• W1673408032 hasConceptScore W1673408032C502942594 @default.
• W1673408032 hasConceptScore W1673408032C54355233 @default.
• W1673408032 hasConceptScore W1673408032C55493867 @default.
• W1673408032 hasConceptScore W1673408032C62478195 @default.
• W1673408032 hasConceptScore W1673408032C75217442 @default.
• W1673408032 hasConceptScore W1673408032C86803240 @default.
• W1673408032 hasConceptScore W1673408032C95444343 @default.
• W1673408032 hasConceptScore W1673408032C96232424 @default.
• W1673408032 hasIssue "11" @default.
• W1673408032 hasLocation W16734080321 @default.
• W1673408032 hasOpenAccess W1673408032 @default.
• W1673408032 hasPrimaryLocation W16734080321 @default.
• W1673408032 hasRelatedWork W1673408032 @default.
• W1673408032 hasRelatedWork W1779463793 @default.

• next